tradingkey.logo

Emergent BioSolutions drops after Syngene buys co's unit for $36.5 mln

ReutersMar 10, 2025 5:24 PM

Shares of drugmaker Emergent BioSolutions EBS.N fall 3% to $5.60, hit nine-month low

India's Syngene International SYNN.NS says it has acquired its first biologics facility in the U.S. from Emergent Manufacturing Operations Baltimore, a unit of EBS, for $36.5 million

The deal is expected to close in March, 2025

Co says the facility is expected to be operational for client projects from the H2 2025

Up to last close, EBS has risen more than double in the past 12 months

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI